查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1954178

HER2阳性乳癌市场分析及预测（至2035年）：依类型、产品类型、服务、技术、组件、应用、最终用户、模式、分期划分

HER2-Positive Breast Cancer Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Component, Application, End User, Mode, Stage
出版日期: | 出版商: Global Insight Services | 英文 306 Pages | 商品交期: 3-5个工作天内

价格
简介目录

预计HER2阳性乳癌市场将从2024年的112亿美元成长到2034年的142亿美元，复合年增长率约为2.8%。 HER2阳性乳癌市场涵盖针对HER2蛋白过度表现的治疗方法，HER2蛋白过度表现会促进癌细胞增生。此类别包括单株抗体、蛋白酪氨酸激酶抑制剂和抗体药物复合体。个人化医疗和标靶治疗的进步正在推动市场扩张，满足未被满足的医疗需求并改善患者预后。盛行率的上升和生物技术的进步也为市场成长奠定了基础。

HER2阳性乳癌市场正经历蓬勃发展，这主要得益于标靶治疗和个人化医疗的进步。单株抗体在治疗领域占据主导地位，在疗效和患者预后方面展现出显着优势。蛋白酪氨酸激酶抑制剂紧随其后，为第一线治疗抗药性的患者提供了极具前景的替代方案。诊断领域持续扩展，分子诊断和伴随诊断在早期检测和个人化治疗中发挥关键作用。基因检测和生物标记鑑定对于制定个人化治疗策略至关重要。新兴的生物相似药展现出竞争优势，并提高了治疗方案的可近性和成本效益。临床试验和研究倡议不断探索新的药物组合和治疗方法，持续推动创新。公众意识的提高和早期诊断有助于提高生存率和患者生活品质。人工智慧在诊断和治疗计画中的应用可望透过优化治疗效果和提升营运效率，进一步变革市场格局。

市场区隔
类型 单株抗体、蛋白酪氨酸激酶抑制剂、免疫疗法、荷尔蒙疗法、化疗、标靶治疗
产品 曲妥珠单抗、Pertuzumab单抗、Lapatinib、来那替尼、图卡替尼、ado-曲妥珠单抗 emtansine、 Margetuximab、fam-曲妥珠单抗 deruxtecan-nxki
服务 诊断服务、治疗服务、咨询服务、后续观察、临床试验和患者援助计划
科技 次世代定序、生物标记检测、伴随诊断、液态生物检体
成分 活性药物成分、製剂及包装
目的 医院使用、诊所使用、居家医疗、研究机构
最终用户 医院、癌症治疗中心、研究机构、学术机构
给药途径 静脉注射和口服给药
步 早期、转移期

HER2阳性乳癌市场正经历市场份额、定价策略和新产品上市方面的动态变化。主要企业正专注于创新治疗方法并推广具有竞争力的定价模式。新型生物製药和标靶治疗的引入显着改善了治疗效果，推动了该市场的蓬勃发展。从区域来看，北美凭藉其先进的医疗基础设施和有利的报销政策，保持着领先地位；而新兴市场则因医疗投资的增加而不断扩大市场份额。竞争基准分析揭示了一个充满活力的市场格局，各大製药公司正透过策略联盟和收购争夺主导。监管的影响至关重要，严格的指导方针左右着药物的核准和市场准入。美国食品药物管理局管理局（FDA）和欧洲药品管理局（EMA）不断调整的政策，强调安全性和有效性，正在显着影响市场动态。市场分析显示，精准医疗正成为显着趋势，精准治疗的发展动能强劲。生物相似药的出现加剧了市场竞争，提供了更具成本效益的替代方案，并有助于提高患者的用药可及性。在技​​术进步和意识提高的推动下，市场正处于成长轨道上。

主要趋势和驱动因素：

由于标靶治疗和个人化医疗的进步，HER2阳性乳癌市场正经历快速成长。关键趋势包括新型HER2标靶治疗的研发，有助于改善患者预后并拓展治疗选择。精准肿瘤学的整合使得有效的治疗方法能够根据个别患者的具体情况量身定制，从而提高疗效并减少副作用。专注于联合治疗的临床试验也蓬勃发展。这些试验旨在提高存活率，并为进行性或抗药性乳癌患者带来新的希望。此外，公众意识的提高和早期诊断的普及正在扩大患者群体，从而推动对创新治疗方法的需求。同时，製药公司之间的策略联盟和伙伴关係正在推动研发活动，并加速最先进治疗的市场化。新兴市场蕴藏着许多机会，这些市场的医疗基础设施正在发展，获得先进治疗的机会也不断增加。能够成功应对监管环境并提供高性价比解决方案的公司将占据有利地位，从而获得可观的市场份额。随着研究不断揭示 HER2 阳性乳癌的复杂性，预计市场将持续成长，为相关人员带来光明前景。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 单株抗体
    • 蛋白酪氨酸激酶抑制剂
    • 免疫疗法
    • 荷尔蒙疗法
    • 化疗
    • 标靶治疗
  • 市场规模及预测：依产品划分
    • 曲妥珠单抗
    • Pertuzumab
    • Lapatinib
    • 奈拉替尼
    • 图卡替尼
    • ado-曲妥珠单抗 emtansine
    • 玛格妥昔单抗
    • Famtrastuzumab deruxtecan-nxki
  • 市场规模及预测：依服务划分
    • 诊断服务
    • 治疗服务
    • 咨询服务
    • 后续护理
    • 临床试验
    • 患者援助计划
  • 市场规模及预测：依技术划分
    • 次世代定序
    • 生物标记检测
    • 伴随诊断
    • 液态生物检体
  • 市场规模及预测：依组件划分
    • 原料药
    • 配方
    • 包装
  • 市场规模及预测：依应用领域划分
    • 医院用途
    • 临床应用
    • 居家医疗
    • 研究所
  • 市场规模及预测：依最终用户划分
    • 医院
    • 癌症治疗中心
    • 研究所
    • 学术机构
  • 市场规模及预测：依管理途径
    • 静脉注射
    • 口服
  • 市场规模及预测：依疾病阶段划分
    • 早期
    • 转移期

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章：公司简介

  • Macro Genics
  • Puma Biotechnology
  • Cytom X Therapeutics
  • Zymeworks
  • Pieris Pharmaceuticals
  • Immunomedics
  • Mersana Therapeutics
  • Molecular Partners
  • Sorrento Therapeutics
  • Oncobiologics
  • Alligator Bioscience
  • Astra Zeneca
  • Cure Vac
  • Glenmark Pharmaceuticals
  • Karyopharm Therapeutics
  • Mabion
  • Bicycle Therapeutics
  • Genmab
  • Bio NTech
  • Immuno Gen

第九章：关于我们

简介目录
Product Code: GIS26121

HER2-Positive Breast Cancer Market is anticipated to expand from $11.2 billion in 2024 to $14.2 billion by 2034, growing at a CAGR of approximately 2.8%. The HER2-Positive Breast Cancer Market encompasses treatments targeting the overexpression of the HER2 protein, which promotes cancer cell growth. This segment includes monoclonal antibodies, tyrosine kinase inhibitors, and antibody-drug conjugates. Advances in personalized medicine and targeted therapies are propelling market expansion, addressing unmet medical needs and improving patient outcomes. The market is poised for growth due to increasing prevalence and advancements in biotechnology.

The HER2-Positive Breast Cancer Market is experiencing dynamic growth, driven by advancements in targeted therapies and personalized medicine. The therapeutic segment takes precedence, with monoclonal antibodies leading in efficacy and patient outcomes. Tyrosine kinase inhibitors closely follow, offering promising alternatives for patients resistant to first-line treatments. The diagnostics segment is expanding, with molecular diagnostics and companion diagnostics playing pivotal roles in early detection and treatment personalization. Genetic testing and biomarker identification are becoming integral in tailoring treatment strategies. Emerging biosimilars present a competitive edge, enhancing accessibility and affordability of treatment options. Clinical trials and research initiatives continue to fuel innovation, with novel drug combinations and treatment regimens under exploration. Increasing awareness and early diagnosis are contributing to improved survival rates and patient quality of life. The integration of artificial intelligence in diagnostics and treatment planning is anticipated to further revolutionize the market, optimizing therapeutic outcomes and operational efficiency.

Market Segmentation
TypeMonoclonal Antibodies, Tyrosine Kinase Inhibitors, Immunotherapy, Hormonal Therapy, Chemotherapy, Targeted Therapy
ProductTrastuzumab, Pertuzumab, Lapatinib, Neratinib, Tucatinib, Ado-trastuzumab Emtansine, Margetuximab, Fam-trastuzumab Deruxtecan-nxki
ServicesDiagnostic Services, Treatment Services, Consultation Services, Follow-up Care, Clinical Trials, Patient Support Programs
TechnologyNext-Generation Sequencing, Biomarker Testing, Companion Diagnostics, Liquid Biopsy
ComponentActive Pharmaceutical Ingredients, Formulations, Packaging
ApplicationHospital Use, Clinic Use, Home Care, Research Institutes
End UserHospitals, Cancer Treatment Centers, Research Laboratories, Academic Institutions
ModeIntravenous, Oral
StageEarly Stage, Metastatic Stage

The HER2-Positive Breast Cancer Market is witnessing dynamic shifts in market share, pricing strategies, and new product launches. Key players are focusing on innovative therapies, driving competitive pricing models. The market is characterized by the introduction of novel biologics and targeted therapies, enhancing treatment efficacy. Geographically, North America maintains a dominant position due to advanced healthcare infrastructure and favorable reimbursement policies, while emerging markets are gaining traction with increased healthcare investments. Competition benchmarking reveals a robust landscape with major pharmaceutical companies vying for leadership through strategic collaborations and acquisitions. Regulatory influences are paramount, with stringent guidelines shaping drug approvals and market entry. The FDA and EMA's evolving policies significantly impact market dynamics, emphasizing safety and efficacy. Market analysis indicates a trend towards personalized medicine, with precision therapies gaining momentum. The competitive intensity is heightened by the entry of biosimilars, offering cost-effective alternatives and expanding patient accessibility. The market's trajectory is set for growth, driven by technological advancements and increased awareness.

Geographical Overview:

The HER2-Positive Breast Cancer Market is witnessing varied growth dynamics across different regions. North America leads, propelled by advanced healthcare infrastructure and substantial R&D investments. The presence of key pharmaceutical players and a high prevalence of breast cancer cases further bolster the market. Europe follows, driven by strong healthcare systems and government support for cancer research. The region's focus on innovative therapies and clinical trials enhances its market position. In Asia Pacific, the market is expanding rapidly due to rising awareness and improved healthcare access. Countries like China and India are emerging as significant growth pockets, supported by increasing healthcare expenditure and a large patient pool. Latin America and the Middle East & Africa are also showing promising potential. In Latin America, growing healthcare investments and awareness campaigns are driving market growth. Meanwhile, the Middle East & Africa are focusing on improving cancer care infrastructure, recognizing the importance of early diagnosis and treatment.

The HER2-Positive Breast Cancer Market is significantly influenced by global tariffs, geopolitical risks, and evolving supply chain dynamics. Japan and South Korea, with their robust pharmaceutical sectors, are navigating trade tensions by enhancing local research capabilities and forging strategic alliances to mitigate import dependencies. China, under export restrictions, is intensifying efforts to boost its biopharmaceutical innovation, aiming for self-reliance. Taiwan, while a critical player in medical technology, remains vulnerable to geopolitical tensions. Globally, the HER2-Positive Breast Cancer Market is poised for growth, driven by advancements in targeted therapies. By 2035, market evolution will hinge on collaborative innovation and resilient supply chains. Middle East conflicts, affecting global energy prices, could indirectly impact pharmaceutical manufacturing costs, influencing market dynamics and strategic planning.

Key Trends and Drivers:

The HER2-Positive Breast Cancer Market is experiencing rapid growth driven by advancements in targeted therapies and personalized medicine. Key trends include the development of novel HER2-targeted treatments, which are enhancing patient outcomes and expanding therapeutic options. The integration of precision oncology is allowing for more effective treatment regimens tailored to individual patient profiles, thereby improving efficacy and reducing adverse effects. The market is also witnessing a surge in clinical trials focusing on combination therapies. These trials aim to improve survival rates and offer new hope for patients with advanced or resistant forms of the disease. Furthermore, increased awareness and early diagnosis are contributing to a growing patient pool, thereby driving demand for innovative treatments. Additionally, strategic collaborations and partnerships among pharmaceutical companies are fostering research and development efforts. This is accelerating the introduction of cutting-edge therapies to the market. Opportunities abound in emerging markets where healthcare infrastructure is evolving, and access to advanced treatments is expanding. Companies that can navigate regulatory landscapes and offer cost-effective solutions are well-positioned to capture significant market share. As research continues to unravel the complexities of HER2-positive breast cancer, the market is poised for sustained growth, offering promising prospects for stakeholders.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Component
  • 2.6 Key Market Highlights by Application
  • 2.7 Key Market Highlights by End User
  • 2.8 Key Market Highlights by Mode
  • 2.9 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Monoclonal Antibodies
    • 4.1.2 Tyrosine Kinase Inhibitors
    • 4.1.3 Immunotherapy
    • 4.1.4 Hormonal Therapy
    • 4.1.5 Chemotherapy
    • 4.1.6 Targeted Therapy
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Trastuzumab
    • 4.2.2 Pertuzumab
    • 4.2.3 Lapatinib
    • 4.2.4 Neratinib
    • 4.2.5 Tucatinib
    • 4.2.6 Ado-trastuzumab Emtansine
    • 4.2.7 Margetuximab
    • 4.2.8 Fam-trastuzumab Deruxtecan-nxki
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Diagnostic Services
    • 4.3.2 Treatment Services
    • 4.3.3 Consultation Services
    • 4.3.4 Follow-up Care
    • 4.3.5 Clinical Trials
    • 4.3.6 Patient Support Programs
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Next-Generation Sequencing
    • 4.4.2 Biomarker Testing
    • 4.4.3 Companion Diagnostics
    • 4.4.4 Liquid Biopsy
  • 4.5 Market Size & Forecast by Component (2020-2035)
    • 4.5.1 Active Pharmaceutical Ingredients
    • 4.5.2 Formulations
    • 4.5.3 Packaging
  • 4.6 Market Size & Forecast by Application (2020-2035)
    • 4.6.1 Hospital Use
    • 4.6.2 Clinic Use
    • 4.6.3 Home Care
    • 4.6.4 Research Institutes
  • 4.7 Market Size & Forecast by End User (2020-2035)
    • 4.7.1 Hospitals
    • 4.7.2 Cancer Treatment Centers
    • 4.7.3 Research Laboratories
    • 4.7.4 Academic Institutions
  • 4.8 Market Size & Forecast by Mode (2020-2035)
    • 4.8.1 Intravenous
    • 4.8.2 Oral
  • 4.9 Market Size & Forecast by Stage (2020-2035)
    • 4.9.1 Early Stage
    • 4.9.2 Metastatic Stage

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Component
      • 5.2.1.6 Application
      • 5.2.1.7 End User
      • 5.2.1.8 Mode
      • 5.2.1.9 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Component
      • 5.2.2.6 Application
      • 5.2.2.7 End User
      • 5.2.2.8 Mode
      • 5.2.2.9 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Component
      • 5.2.3.6 Application
      • 5.2.3.7 End User
      • 5.2.3.8 Mode
      • 5.2.3.9 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Component
      • 5.3.1.6 Application
      • 5.3.1.7 End User
      • 5.3.1.8 Mode
      • 5.3.1.9 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Component
      • 5.3.2.6 Application
      • 5.3.2.7 End User
      • 5.3.2.8 Mode
      • 5.3.2.9 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Component
      • 5.3.3.6 Application
      • 5.3.3.7 End User
      • 5.3.3.8 Mode
      • 5.3.3.9 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Component
      • 5.4.1.6 Application
      • 5.4.1.7 End User
      • 5.4.1.8 Mode
      • 5.4.1.9 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Component
      • 5.4.2.6 Application
      • 5.4.2.7 End User
      • 5.4.2.8 Mode
      • 5.4.2.9 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Component
      • 5.4.3.6 Application
      • 5.4.3.7 End User
      • 5.4.3.8 Mode
      • 5.4.3.9 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Component
      • 5.4.4.6 Application
      • 5.4.4.7 End User
      • 5.4.4.8 Mode
      • 5.4.4.9 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Component
      • 5.4.5.6 Application
      • 5.4.5.7 End User
      • 5.4.5.8 Mode
      • 5.4.5.9 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Component
      • 5.4.6.6 Application
      • 5.4.6.7 End User
      • 5.4.6.8 Mode
      • 5.4.6.9 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Component
      • 5.4.7.6 Application
      • 5.4.7.7 End User
      • 5.4.7.8 Mode
      • 5.4.7.9 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Component
      • 5.5.1.6 Application
      • 5.5.1.7 End User
      • 5.5.1.8 Mode
      • 5.5.1.9 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Component
      • 5.5.2.6 Application
      • 5.5.2.7 End User
      • 5.5.2.8 Mode
      • 5.5.2.9 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Component
      • 5.5.3.6 Application
      • 5.5.3.7 End User
      • 5.5.3.8 Mode
      • 5.5.3.9 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Component
      • 5.5.4.6 Application
      • 5.5.4.7 End User
      • 5.5.4.8 Mode
      • 5.5.4.9 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Component
      • 5.5.5.6 Application
      • 5.5.5.7 End User
      • 5.5.5.8 Mode
      • 5.5.5.9 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Component
      • 5.5.6.6 Application
      • 5.5.6.7 End User
      • 5.5.6.8 Mode
      • 5.5.6.9 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Component
      • 5.6.1.6 Application
      • 5.6.1.7 End User
      • 5.6.1.8 Mode
      • 5.6.1.9 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Component
      • 5.6.2.6 Application
      • 5.6.2.7 End User
      • 5.6.2.8 Mode
      • 5.6.2.9 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Component
      • 5.6.3.6 Application
      • 5.6.3.7 End User
      • 5.6.3.8 Mode
      • 5.6.3.9 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Component
      • 5.6.4.6 Application
      • 5.6.4.7 End User
      • 5.6.4.8 Mode
      • 5.6.4.9 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Component
      • 5.6.5.6 Application
      • 5.6.5.7 End User
      • 5.6.5.8 Mode
      • 5.6.5.9 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Macro Genics
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Puma Biotechnology
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Cytom X Therapeutics
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Zymeworks
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Pieris Pharmaceuticals
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Immunomedics
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Mersana Therapeutics
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Molecular Partners
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Sorrento Therapeutics
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Oncobiologics
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Alligator Bioscience
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Astra Zeneca
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Cure Vac
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Glenmark Pharmaceuticals
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Karyopharm Therapeutics
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Mabion
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Bicycle Therapeutics
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Genmab
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Bio NTech
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Immuno Gen
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us